Author: admin

The Heparin-induced Thrombocytopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage pipeline products will significantly revolutionize the Heparin-induced Thrombocytopenia market dynamics. 

DelveInsight’s “Heparin-induced Thrombocytopenia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Heparin-induced Thrombocytopenia, historical and forecasted epidemiology as well as the Heparin-induced Thrombocytopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. 

To Know in detail about the Heparin-induced Thrombocytopenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Heparin-induced Thrombocytopenia Market Forecast

Heparin-induced Thrombocytopenia Market Report’s Key Highlights:

• The Heparin-induced Thrombocytopenia market size was valued approximately USD 128 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

• The United States accounted for approximately half of the total market within the 7MM.

• In 2023, Germany had the largest market share among the EU4 and the UK, making up about 40% of the total market size.

• In 2023, Japan contributed around USD 3 million to the market size, with steady growth anticipated through 2034.

• VLX-1005 (Veralox Therapeutics) is the only therapy currently being studied for the treatment of heparin-induced thrombocytopenia (HIT). In June 2022, the FDA granted fast track designation to VLX-1005 following positive Phase I trial results.

• In 2023, there were approximately 220,800 newly diagnosed cases of HIT. The United States accounted for the largest portion among the 7MM, representing around 51% of the total cases.

• Within the EU4 and the UK, Germany reported the highest number of new HIT cases, followed by France, which contributed about 23% of the total incident cases.

• In 2023, the estimated total incident cases of HIT in the US by type-specific heparin exposure were approximately 107,000 for unfractionated heparin (UFH) and around 6,000 cases for low molecular-weight heparin (LMWH).

• Key Heparin-induced Thrombocytopenia Companies: Sandoz, Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines Company, Canyon Pharma, and others

• Key Heparin-induced Thrombocytopenia Therapies: ANGIOMAX (bivalirudin), argatroban, VLX-1005, bivalirudin, Desirudin (Iprivask™), and others

• The Heparin-induced Thrombocytopenia epidemiology based on gender analyzed that higher number of cases of Heparin-induced Thrombocytopenia were observed in males as compared to females

• The Heparin-induced Thrombocytopenia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Heparin-induced Thrombocytopenia pipeline products will significantly revolutionize the Heparin-induced Thrombocytopenia market dynamics

Heparin-induced Thrombocytopenia Overview:

Heparin-induced Thrombocytopenia (HIT) is a rare but serious immune reaction to the anticoagulant heparin. It occurs when the body’s immune system forms antibodies against complexes of heparin and platelet factor 4, leading to the activation of platelets and an increased risk of thrombosis (blood clots). This condition can cause a significant drop in platelet count (thrombocytopenia) and result in severe complications, including deep vein thrombosis, pulmonary embolism, or stroke. HIT is most commonly associated with heparin treatment, especially after prol onged use. It requires prompt diagnosis and discontinuation of heparin, often followed by alternative anticoagulation therapy.

Request a sample for the Heparin-induced Thrombocytopenia Market Report:

https://www.delveinsight.com/report-store/heparin-induced-thrombocytopenia-market

Heparin-induced Thrombocytopenia Country based Treatment Analysis: 

The Heparin-induced Thrombocytopenia treatment market report provides treatment regimen across the 7MM. It will help companies to analyze the practices followed across 7MM, patient journey and advances in Heparin-induced Thrombocytopenia Therapies that have the potential to transform cancer treatment paradigms and improve patient outcomes.

Heparin-induced Thrombocytopenia Epidemiology Insights: 

The report offers historical and forecasted epidemiology insights that helps to understand the target patient population for Heparin-induced Thrombocytopenia. The analysis is from 2020-2034, providing insights how the patient trends are going to shape the market dynamics. Further, the epidemiology is segmented to provide in-depth analysis of patient pools allowing companies to understand their target patients pools. The epidemiology in report is segmented as : 

Heparin-induced Thrombocytopenia Epidemiology Segmentation:

• Total Prevalence of Heparin-induced Thrombocytopenia

• Prevalent Cases of Heparin-inducedThrombocytopenia by severity

• Gender-specific Prevalence of Heparin-induced Thrombocytopenia

• Diagnosed Cases of Episodic and Chronic Heparin-induced Thrombocytopenia

Download the report to understand which factors are driving Heparin-induced Thrombocytopenia epidemiology trends @ Heparin-induced Thrombocytopenia Epidemiology Forecast

Emerging Heparin-induced Thrombocytopenia drugs Uptake:

• VLX-1005, a novel treatment for Heparin-induced Thrombocytopenia (HIT), is presently undergoing Phase II clinical studies. The few main therapies for HIT that are now available are listed below.

• There are also a number of new oral anticoagulants on the market, such as dabigatran, apixaban, and rivaroxaban, and preliminary data indicates that they could be helpful for HIT, especially in situations where conventional treatments are ineffective. None of these medications have FDA approval for use in HIT, and their efficacy in treating individuals with HIT has not yet been thoroughly evaluated.

Heparin-induced Thrombocytopenia Market Forecast :

• The research includes a thorough analysis of the past and projected markets for Heparin-induced Thrombocytopenia (HIT), which includes pharmacological outreach in the 7MM nations.

• Rise in the cases of heparin-induced thrombocytopenia due to various risk factors, such as increased cardiac and orthopedic surgeries and the continued use of unfractionated heparin in hospitalized patients

• The emergence of direct oral anticoagulants (DOACs) as an alternative for parenteral anticoagulants in acute HIT or HIT with thrombosis is a significant strength in the HIT market. DOACs offer convenience, ease of administration, and comparable efficacy to traditional parenteral anticoagulants 

Heparin-induced Thrombocytopenia Therapies and Key Companies

• ANGIOMAX (bivalirudin): Sandoz

• argatroban: Mitsubishi Tanabe Pharma

• VLX-1005: Veralox Therapeutics

• bivalirudin: The Medicines Company

• Desirudin (Iprivask™): Canyon Pharma

Discover more about therapies set to grab major Heparin-induced Thrombocytopenia market share @ Heparin-induced Thrombocytopenia Treatment Market

Scope of the Heparin-induced Thrombocytopenia Market Report

• Study Period: 2020–2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Heparin-induced Thrombocytopenia Companies: Sandoz, Phantom Pharmaceuticals, Sinorda Biomedicine, Sebela Pharmaceutical, Cinclus Pharma, Renexxion Ireland, Daewoong Pharmaceutical, AstraZeneca, Aurobindo Pharma Limited, Cadila Pharmaceuticals Limited, Camber Pharmaceuticals Inc., CHEPLAPHARM Arzneimittel GmbH, Daewoong Pharmaceutical Co, HK inno.N, Chong Kun Dang Pharmaceutical, Addpharma, Jeil Pharmaceuticals, Renexxion, Daewoong Pharmaceutical, and others

• Key Heparin-induced Thrombocytopenia Therapies: ANGIOMAX (bivalirudin), Vonoprazan, X842, BLI5100, Linaprazan glurate, Naronapride, Fexuprazan, IN-C003, IN-C002, CKD-382, IN-C004, AD-214: , JP-1366, Naronapride, Fexuprazan, and others

• Heparin-induced Thrombocytopenia Therapeutic Assessment: Heparin-induced Thrombocytopenia current marketed and Heparin-induced Thrombocytopenia emerging therapies

• Heparin-induced Thrombocytopenia Market Dynamics: Heparin-induced Thrombocytopenia market drivers and Heparin-induced Thrombocytopenia market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Heparin-induced Thrombocytopenia Unmet Needs, KOL’s views, Analyst’s views, Heparin-induced Thrombocytopenia Market Access and Reimbursement 

DelveInsight’s report offers comprehensive insights, market analysis, and forecasts aiding leading companies in strategic decision-making for the Heparin-induced Thrombocytopenia market landscape.

• Gain Competitive Edge in Indication Market : Understand the current landscape of the heparin-induced thrombocytopenia market, including the competitive environment, key companies developing drugs for Heparin-induced Thrombocytopenia, and their strategies. By analyzing market dynamics, treatment approaches, and emerging therapies, stakeholders can identify opportunities to position themselves effectively, gaining a competitive edge over others.

• Identify Market Gaps and indication market opportunities : Analyzing epidemiological trends, country wise patient journeys and existing treatment practices can help in identifying gaps and opportunities within the heparin-induced thrombocytopenia market. This involves recognizing areas where current treatments may be insufficient or where there is an unmet need. The report is curated by taking account of various KOLs dealing  with  Heparin-induced Thrombocytopenia. Identifying these gaps allows stakeholders to explore new therapeutic avenues, potentially leading to the development of novel treatments that address specific market needs and price their emerging products strategically to gain a competitive edge.

• Strategic decision making : Armed with insights from epidemiological and market forecasts, stakeholders can make informed and strategic decisions. This may involve deciding on research and development investments, portfolio expansion, pricing – reimbursement strategies, partnerships, or other strategic moves. Understanding the market dynamics enables stakeholders to align their goals with the prevailing trends and future projections.

• Plan RoadMap to Success : Through this report the leading companies can set short-term and long-term goals, define strategies for market penetration, and outline steps for product development or market expansion. A well-informed roadmap ensures that stakeholders navigate the complexities of the heparin-induced thrombocytopenia market with clarity and purpose.

To know more about Heparin-induced Thrombocytopenia companies working in the treatment market, visit @ Heparin-induced Thrombocytopenia Clinical Trials and Therapeutic Assessment

Table of Contents

1. Heparin-induced Thrombocytopenia Report Introduction

2. Heparin-induced Thrombocytopenia Executive Summary

3. Heparin-induced Thrombocytopenia Overview

4. Heparin-induced Thrombocytopenia- Analytical Perspective In-depth Commercial Assessment

5. Heparin-induced Thrombocytopenia Pipeline Therapeutics

6. Heparin-induced Thrombocytopenia Late Stage Products (Phase II/III)

7. Heparin-induced Thrombocytopenia Mid Stage Products (Phase II)

8. Heparin-induced Thrombocytopenia Early Stage Products (Phase I)

9. Heparin-induced Thrombocytopenia Preclinical Stage Products

10. Heparin-induced Thrombocytopenia Therapeutics Assessment

11. Heparin-induced Thrombocytopenia Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Heparin-induced Thrombocytopenia Key Companies

14. Heparin-induced Thrombocytopenia Key Products

15. Heparin-induced Thrombocytopenia Unmet Needs

16 . Heparin-induced Thrombocytopenia Market Drivers and Barriers

17. Heparin-induced Thrombocytopenia Future Perspectives and Conclusion

18. Heparin-induced Thrombocytopenia Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Heparin Induced Thrombocytopenia Market Growth to Accelerate in Forecast Period (2024-2034), DelveInsight Analyzes | Canyon Pharma, Mitsubishi Tanabe Pharma, Veralox Therapeutics, The Medicines

The Hand Eczema market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hand Eczema pipeline products will significantly revolutionize the Hand Eczema market dynamics.  

DelveInsight’s “Hand Eczema Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Hand Eczema, historical and forecasted epidemiology as well as the Hand Eczema market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Hand Eczema market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hand Eczema Market Forecast

Some of the key facts of the Hand Eczema Market Report:  

• The Hand Eczema market size was valued approximately USD 11.5 billion in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032) 

• In September 2024, LEO Pharma A/S, a global leader in medical dermatology, has unveiled late-breaking data from the DELTA FORCE trial and presented six additional abstracts during the scientific program, highlighting Anzupgo® (delgocitinib) cream as a potential treatment for adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are insufficient or unsuitable.

• Hand Eczema prevalence is difficult to estimate because not all patients seek treatment. It is estimated that hand eczema affects 2% to 10% of the general population 

• In 2021, the number of existing cases of hand eczema was highest in the United States, totaling around 26,000,000 cases, while Spain had the lowest prevalence with approximately 4,000,000 cases.

• In 2021, around 11,000,000 males and 16,000,000 females in the United States were impacted by hand eczema. Projections suggest that the prevalence will rise, reaching approximately 11,555,000 among males and 16,800,000 among females by 2032.

• In 2021, Germany had the highest prevalence of hand eczema among the EU4 and the UK, with over 7,000,000 reported cases.

• The lack of approved treatments for this condition demonstrates that there is a clear need for more targeted therapies that limit and control this burdensome disease. In terms of future competition, additional products are entering the market along with new technologies 

• Key Hand Eczema Companies: Incyte Corporation, University Medical Center Groningen, ACO Hud Nordic AB, LEO Pharma, Arcutis Biotherapeutics, Inc., Asana BioSciences, Basilea Pharmaceutica, Innovaderm Research Inc., Stiefel, a GSK Company, and others 

• Key Hand Eczema Therapies: Ruxolitinib cream, Dupilumab, betamethasone valerate, LEO 124249, ARQ-252, ASN002, alitretinoin, Acitretin, clobetasol propionate, and others 

• The Hand Eczema epidemiology based on gender analyzed that Hand Eczema is more common in males, than females  

• The hand eczema cases were categorized into specific age groups: 18-30, 31-40, 41-50, 50-60, and 60 years and above.

Hand Eczema Overview

Hand eczema, also known as dermatitis, is a common type of eczema that primarily affects the palms but can also involve other parts of the hand. 

Get a Free sample for the Hand Eczema Market Report: 

https://www.delveinsight.com/report-store/hand-eczema-market

Hand Eczema Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Hand Eczema Epidemiology Segmentation:

The Hand Eczema market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Hand Eczema

• Prevalent Cases of Hand Eczema by severity

• Gender-specific Prevalence of Hand Eczema

• Diagnosed Cases of Hand Eczema 

Download the report to understand which factors are driving Hand Eczema epidemiology trends @ Hand Eczema Epidemiological Insights

Hand Eczema Market  

The dynamics of the Hand Eczema market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2019-2032. 

Hand Eczema Therapies and Key Companies

• Ruxolitinib cream: Incyte Corporation

• Dupilumab: University Medical Center Groningen

• betamethasone valerate: ACO Hud Nordic AB

• LEO 124249: LEO Pharma

• ARQ-252: Arcutis Biotherapeutics, Inc.

• ASN002: Asana BioSciences

• alitretinoin: Basilea Pharmaceutica

• Acitretin: Innovaderm Research Inc.

• clobetasol propionate: Stiefel, a GSK Company

To know more about Hand Eczema treatment, visit @ Hand Eczema Medications

Hand Eczema Market Drivers

• Government Initiatives 

• Growth in Research and Development 

• Increase in the number of patients

Hand Eczema Market Barriers

• Lack of Approved Hand Eczema therapies 

• Lack of Clinical Trial studies

Scope of the Hand Eczema Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Hand Eczema Companies: Incyte Corporation, University Medical Center Groningen, ACO Hud Nordic AB, LEO Pharma, Arcutis Biotherapeutics, Inc., Asana BioSciences, Basilea Pharmaceutica, Innovaderm Research Inc., Stiefel, a GSK Company, and others

• Key Hand Eczema Therapies: Ruxolitinib cream, Dupilumab, betamethasone valerate, LEO 124249, ARQ-252, ASN002, alitretinoin, Acitretin, clobetasol propionate, and others

• Hand Eczema Therapeutic Assessment: Hand Eczema current marketed and Hand Eczema emerging therapies

• Hand Eczema Market Dynamics:  Hand Eczema market drivers and Hand Eczema market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Hand Eczema Unmet Needs, KOL’s views, Analyst’s views, Hand Eczema Market Access and Reimbursement 

Discover more about therapies set to grab major Hand Eczema market share @ Hand Eczema market forecast

Table of Contents 

1. Hand Eczema Market Report Introduction

2. Executive Summary for Hand Eczema

3. SWOT analysis of Hand Eczema

4. Hand Eczema Patient Share (%) Overview at a Glance

5. Hand Eczema Market Overview at a Glance

6. Hand Eczema Disease Background and Overview

7. Hand Eczema Epidemiology and Patient Population

8. Country-Specific Patient Population of Hand Eczema 

9. Hand Eczema Current Treatment and Medical Practices

10. Hand Eczema Unmet Needs

11. Hand Eczema Emerging Therapies

12. Hand Eczema Market Outlook

13. Country-Wise Hand Eczema Market Analysis (2019–2032)

14. Hand Eczema Market Access and Reimbursement of Therapies

15. Hand Eczema Market Drivers

16. Hand Eczema Market Barriers

17.  Hand Eczema Appendix

18. Hand Eczema Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hand Eczema Market on Track for Major Expansion by 2032, According to DelveInsight | LEO Pharma, Asana Biosciences, Incyte Corporation